Patent classifications
A61L2300/232
Compositions and methods for delivering an agent to a wound
The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
ABSORBENT ARTICLE WITH ODOR CONTROL COMPOSITION
A disposable absorbent article having a topsheet, a backsheet, and an absorbent core disposed between the topsheet and the backsheet is described. The disposable absorbent article includes an odor control composition having a preservative, a surfactant, methylated beta-cyclodextrin (m-BCD), and perfume.
METHODS FOR ANEURYSM TREATMENT
Disclosed herein is a method of producing high purity pentagalloyl glucose (PGG), analogues or derivatives thereof, at least 99.9% pure, by washing with dimethyl ether. PGG may be provided in a kit, including a hydrolyzer for dissolving the PGG and a saline solution. Also disclosed herein is a device for delivery of a therapeutic solution to a blood vessel. The device may be a catheter having an upstream balloon and a downstream balloon. The upstream balloon may be expanded to anchor the catheter and occlude antegrade blood flow. The downstream balloon may be expanded to occlude retrograde blood flow, creating a sealed volume within the blood vessel. The downstream balloon may have pores configured to deliver a therapeutic inflation solution into the sealed volume or a portion thereof. The downstream balloon may be expanded by the expansion of a balloon disposed inside the downstream balloon.
LIQUID EMBOLIC MATERIAL COMPOSITION
A liquid embolic composition of natural polymers, water, and angiographic contrast agents improves neurovascular interventions, making them more reliable, safe, and affordable. The embolic material is made of a single component activated by blood calcium ion, which triggers coagulation, and that offers superior mechanical stability and does not cause fragmentation in the target vessel. The material retains superior long-term mechanical durability after deployment and provides sufficient visualization under fluoroscopy with iodine-based angiographic contrast compounds or other radiopaque compositions. Described herein are aqueous solutions that enable a high concentration gellan gum (greater than 0.5 wt %) to retain sol state even at the range of body temperature (30-40° C.). This discovery means that it is possible to increase the concentration of gellan gum without losing its inject-ability, yet significantly improve its mechanical stability after delivery.
COMPOSITIONS AND METHODS FOR DELIVERING AN AGENT TO A WOUND
The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
Powder for achieving hemostasis
In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.
Bio-Material Composition and Methods of Use
The present disclosure relates to a bio-material composition comprising a dry potassium phosphate based mixture omprising: MgO, monobasic potassium phosphate, monobasic sodium phosphate, proteoglycans, calcium sodium phosphosilicate, and an antibiotic, wherein a weight percent ratio of monobasic potassium phosphate to MgO is between about 3:1 and 1:1, wherein the dry otassium phosphate based mixture is configured to be mixed with the aqueous solution to thereby form a reabsorbable bio-material slurry, wherein the proteoglycans are between about 1-10 weight percent of the dry composition, and wherein the proteoglycans act as active regulators of collagen fibrillogenesis to thereby structure tissue of a patient by organizing a bone extracellular matrix.
TISSUE THICKNESS COMPENSATOR COMPRISING AT LEAST ONE MEDICAMENT
In various embodiments, a tissue thickness compensator can comprise one or more capsules and/or pockets comprising at least one medicament therein. In at least one embodiment, staples can be fired through the tissue thickness compensator to rupture the capsules. In certain embodiments, a firing member, or knife, can be advanced through the tissue thickness compensator to rupture the capsules.
FIBRINOGEN AND THROMBIN SOLUTIONS FOR A FIBRIN SEALANT AND FIBRIN SEALANT KIT
Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg/ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water. The thrombin activity decreases at most by 15% after storing the solution at 25° C. for 14 days. Also disclosed is a fibrin sealant kit with a first container comprising the fibrinogen solution and a second container comprising the thrombin solution. Further, methods for preparing a fibrin sealant and methods for treating a wound are disclosed.
ECOBIOLOGICAL TREATMENT OF SIDE EFFECTS OF RADIOTHERAPY
The present invention concerns a three-dimensional bipolymeric matrix deploying biological and biomechanical activity, able to neutralize the various physiopathological parameters involved in the development and worsening of skin lesions and/or sores, combining: a first polymeric network comprising first colloids (Col-1) bonded non-covalently to an unsulfated crosslinked polysaccharide; and a second polymeric network comprising second colloids (Col-2) bonded covalently or non-covalently to a sulfated polysaccharide.